Abstract
Our previous study has reported that mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) regulates the growth and survival of hepatocellular carcinoma (HCC) cells. This study was undertaken to explore the roles of MAP4K4 in the epithelial-mesenchymal transition (EMT) and metastasis in HCC. Effects of overexpression and knockdown of MAP4K4 on the migration, invasion, and EMT of HCC cells were examined. The in vivo role of MAP4K4 in lung metastasis of HCC was determined in nude mice. The relationship between MAP4K4 expression and EMT in human HCC specimens was determined by immunohistochemistry. MAP4K4 overexpression significantly enhanced the migration and invasion of MHCC-97L HCC cells, whereas MAP4K4 silencing hindered the migration and invasion of MHCC-97H HCC cells. MAP4K4-overexpressing cells undergo EMT, which was accompanied by downregulation of E-cadherin and upregulation of vimentin. In contrast, MAP4K4 silencing caused a reversion from a spindle morphology to cobblestone-like morphology and induction of E-cadherin and reduction of vimentin. Pretreatment with chemical inhibitors of JNK and NF-κB abolished MAP4K4-mediated migration, invasion, and regulation of EMT markers in MHCC-97L cells. Ectopic expression of MAP4K4 promoted and knockdown of MAP4K4 inhibited lung metastasis of HCC, which was associated with regulation of JNK and NF-κB signaling and EMT markers. High MAP4K4 immunoreactivity was inversely correlated with E-cadherin and was positively correlated with vimentin, phospho-JNK, and phospho-NF-κB in HCC specimens. Taken together, MAP4K4 promotes the EMT and invasiveness of HCC cells largely via activation of JNK and NF-κB signaling.
Similar content being viewed by others
References
Boyle P, Levin B. World cancer report 2008. Avenue, Geneva, Switzerland: WHO Press; 2009. p. 350.
Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.
Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223–37.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99:392–7.
Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; pii: E17
Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016. doi: 10.18632/oncotarget.7016.
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.
Dai W, Wang F, He L, Lin C, Wu S, Chen P, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor nfat1. Mol Carcinog. 2015;54:301–11.
Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35:479–88.
Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, et al. Map4k4 regulates integrin-ferm binding to control endothelial cell motility. Nature. 2015;519:425–30.
Yue J, Xie M, Gou X, Lee P, Schneider MD, Wu X. Microtubules regulate focal adhesion dynamics through map4k4. Dev Cell. 2014;31:572–85.
Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies map4k4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103:3775–80.
Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. Shrna-targeted map4k4 inhibits hepatocellular carcinoma growth. Clin Cancer Res. 2011;17:710–20.
Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of map4k4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14:7043–9.
Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. Mirna-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting map4k4. Mol Cancer Ther. 2013;12:2569–80.
Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34:2548–57.
Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, et al. Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. Carcinogenesis. 2014;35:1855–62.
Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of map4k4 in lung adenocarcinoma. Pathol Res Pract. 2012;208:541–8.
Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. P38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell. 2006;125:957–69.
Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, et al. Rankl promotes migration and invasion of hepatocellular carcinoma cells via NF-kappab-mediated epithelial-mesenchymal transition. PLoS One. 2014;9, e108507.
Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappab drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60:1659–73.
Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–8.
Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of mkk4/JNK via NF-kappab mediated urokinase plasminogen activator expression. PLoS One. 2014;9, e86537.
Zhu XL, Wang YL, Chen JP, Duan LL, Cong PF, Qu YC, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014;35:1627–35.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported in part by grants from National Nature Science Foundation of China (No. 81072020 and 81172311 to S.H. Zhang) and from “085” and “Integrated Traditional Chinese and Western Medicine” first-class discipline construction of science and technology innovation in Shanghai University of Traditional Chinese Medicine (No. 085ZY1220 to S.H. Zhang).
Conflict of interest
None
Additional information
Highlights
MAP4K4 promotes the EMT and invasiveness of HCC cells.
Inhibitors of JNK and NF-κB abolishes MAP4K4-mediated migration, invasion, and EMT.
Ectopic expression of MAP4K4 facilitates lung metastasis of HCC.
Rights and permissions
About this article
Cite this article
Feng, XJ., Pan, Q., Wang, SM. et al. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Tumor Biol. 37, 11457–11467 (2016). https://doi.org/10.1007/s13277-016-5022-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-5022-1